ArticleThe Journal of experimental medicine2026
SorLA regulates B cell receptor uptake, trafficking, and B cell-mediated immune responses in vivo.
Melibea Berzosa, Adam N McShane, Anna E Kliszczak, Aure Aflalo, Pratiti Nanda, Yixuan Shen, Manon H Williams, Fiona Hills, Chloe M Shepherd, Kevin O Saunders and 5 more
Abstract read
In one paragraphArticle in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Melibea Berzosa *Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast , Belfast, UK.ORCID 0000-0003-3087-5273 Adam N McShane *Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast , Belfast, UK.ORCID 0000-0002-0651-2942 Anna E KliszczakNuffield Department of Clinical Medicine, Centre for Immuno-Oncology, University of Oxford, Oxford, UK.ORCID 0009-0000-5444-9792 Aure AflaloNuffield Department of Clinical Medicine, Centre for Immuno-Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-7158-6868 Pratiti NandaWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast , Belfast, UK.ORCID 0009-0005-9155-7297 Yixuan ShenWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast , Belfast, UK.ORCID 0009-0003-1464-0842 Manon H WilliamsWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast , Belfast, UK.ORCID 0009-0008-0762-7064 Fiona HillsWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast , Belfast, UK.ORCID 0009-0003-1257-1783 Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Duke University , Durham, NC, USA.ORCID 0000-0001-7399-7954 S Munir AlamDuke Human Vaccine Institute, Duke University School of Medicine, Duke University , Durham, NC, USA.ORCID 0000-0003-0941-0703 Nicola TernetteNuffield Department of Clinical Medicine, Centre for Immuno-Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-9283-0743 Persephone BorrowNuffield Department of Clinical Medicine, Centre for Immuno-Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-3877-9780 Dessislava MalinovaWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast , Belfast, UK.ORCID 0000-0003-0784-5703 Funding
Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4MProject 3 - Dynamics of latent HIV-1 reservoirs: High resolution antigenic mapping and strategies to block reboundU54AI170752 · NIAID · DUKE UNIVERSITY · PI Priyamvada Acharya · 2022 to 2026
$32.0MLeukaemia and Lymphoma NI R2884CEMMedical Research Council MR/W025868/1National Institute of Allergy and Infectious Diseases U54-AI170752National Institute of Allergy and Infectious Diseases UM1-AI144371NIAID NIH HHS U54 AI170752NIAID NIH HHS UM1 AI144371NIH HHSQueen's University BelfastRoyal Society RGS\R2\212016
6 · The paper itselfAbstract
A high-affinity antibody response to both infection and vaccination critically relies on the ability of B cells to capture and process antigen for presentation to CD4+ T cells. The cellular processes from antigen recognition to full B cell activation require a finely orchestrated series of events, involving signalling and intracellular trafficking mechanisms. Here, we describe a novel regulator of B cell receptor (BCR) endocytosis and intracellular trafficking. Multidomain trafficking protein sorting-related receptor with A-type repeats (SorLA) associates with the BCR and regulates uptake of both soluble and substrate-bound antigens. SorLA deletion results in altered BCR-antigen intracellular trafficking to degradative compartments, modulating eventual antigen presentation. Crucially, this change in antigen trafficking results in a significant reduction in plasma cells and humoral responses in vivo. Given the critical importance of antigen presentation in immunity, as well as autoimmune disease and malignancy, these results identify a new cellular pathway in B cell biology with potential implications for immune regulation.
Indexed as
B-LymphocytesImmunity, CellularLDL-Receptor Related ProteinsMembrane Transport ProteinsReceptors, Antigen, B-CellAnimalsAntigen PresentationEndocytosisHumansMiceMice, Inbred C57BLMice, KnockoutProtein TransportLDL-Receptor Related ProteinsMembrane Transport ProteinsReceptors, Antigen, B-Cell
Identifiers
PMID42550176
PMCPMC13435973
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390